[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C

a pooled analysis].

Soo Yong Park, Min Young Rim, I. K. Yo, Min Su Ha, Ju Seung Kim, Ji Won Lee, Young Kul Jung, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Ju Hyun Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9% (290/326) and 64.4% (491/762) respectively and 88.8% (135/152), and 79.4% (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3% (1,981/3,860) and 42.4% (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns.

Original languageEnglish
Pages (from-to)306-314
Number of pages9
JournalThe Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi
Volume60
Issue number5
Publication statusPublished - 2012 Nov 1
Externally publishedYes

Fingerprint

Ribavirin
Chronic Hepatitis C
Genotype
Korea
Therapeutic Uses
Therapeutics
Sustained Virologic Response

ASJC Scopus subject areas

  • Medicine(all)

Cite this

[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C : a pooled analysis]. / Park, Soo Yong; Rim, Min Young; Yo, I. K.; Ha, Min Su; Kim, Ju Seung; Lee, Ji Won; Jung, Young Kul; Kwon, Oh Sang; Kim, Yun Soo; Choi, Duck Joo; Kim, Ju Hyun.

In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, Vol. 60, No. 5, 01.11.2012, p. 306-314.

Research output: Contribution to journalArticle

Park, SY, Rim, MY, Yo, IK, Ha, MS, Kim, JS, Lee, JW, Jung, YK, Kwon, OS, Kim, YS, Choi, DJ & Kim, JH 2012, '[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].', The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, vol. 60, no. 5, pp. 306-314.
Park, Soo Yong ; Rim, Min Young ; Yo, I. K. ; Ha, Min Su ; Kim, Ju Seung ; Lee, Ji Won ; Jung, Young Kul ; Kwon, Oh Sang ; Kim, Yun Soo ; Choi, Duck Joo ; Kim, Ju Hyun. / [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C : a pooled analysis]. In: The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi. 2012 ; Vol. 60, No. 5. pp. 306-314.
@article{07d2cea0fab441a39a55af15da3dee05,
title = "[Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C: a pooled analysis].",
abstract = "A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6{\%} (125/157), 80.1{\%} (166/207), and 62.7{\%} (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4{\%} (119/133), 92.2{\%} (203/220), and 84.1{\%} (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9{\%} (290/326) and 64.4{\%} (491/762) respectively and 88.8{\%} (135/152), and 79.4{\%} (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3{\%} (1,981/3,860) and 42.4{\%} (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7{\%} (350/399) and 77.8{\%} (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns.",
author = "Park, {Soo Yong} and Rim, {Min Young} and Yo, {I. K.} and Ha, {Min Su} and Kim, {Ju Seung} and Lee, {Ji Won} and Jung, {Young Kul} and Kwon, {Oh Sang} and Kim, {Yun Soo} and Choi, {Duck Joo} and Kim, {Ju Hyun}",
year = "2012",
month = "11",
day = "1",
language = "English",
volume = "60",
pages = "306--314",
journal = "The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi",
issn = "1598-9992",
publisher = "Korean Society of Gastroenterology",
number = "5",

}

TY - JOUR

T1 - [Efficacy of peginterferon and ribavirin combination therapy of chronic hepatitis C

T2 - a pooled analysis].

AU - Park, Soo Yong

AU - Rim, Min Young

AU - Yo, I. K.

AU - Ha, Min Su

AU - Kim, Ju Seung

AU - Lee, Ji Won

AU - Jung, Young Kul

AU - Kwon, Oh Sang

AU - Kim, Yun Soo

AU - Choi, Duck Joo

AU - Kim, Ju Hyun

PY - 2012/11/1

Y1 - 2012/11/1

N2 - A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9% (290/326) and 64.4% (491/762) respectively and 88.8% (135/152), and 79.4% (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3% (1,981/3,860) and 42.4% (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns.

AB - A combination of peginterferon and ribavirin is the standard therapy for chronic hepatitis C (CHC). However, the respective study has not been carried out in a large scale in Korea. The purpose of this study was to collect the studies that have been reported in Korea in order to analyze the therapeutic effect of combination therapy and compare to find racial difference. Twenty-eight papers related to the therapeutic effect of combination therapy in CHC patients were analyzed based on pooled analysis. Based on the analysis for genotype 1 in Korea, early virologic response (EVR), end of treatment response (ETR), and sustained virologic response (SVR) were 79.6% (125/157), 80.1% (166/207), and 62.7% (341/543). The EVR, ETR, and SVR for genotype 2 and 3 were 89.4% (119/133), 92.2% (203/220), and 84.1% (434/516). Data from other Asians showed that EVR and SVR for genotype 1 were 88.9% (290/326) and 64.4% (491/762) respectively and 88.8% (135/152), and 79.4% (151/190) for genotype 2 and 3 respectively. In Western, EVR and SVR for genotype 1 were 51.3% (1,981/3,860) and 42.4% (1,798/4,231) respectively, and for genotype 2 and 3 were 87.7% (350/399) and 77.8% (533/685) respectively. Based on the comparative analysis, no statistical difference in SVR between Koreans and other Asians (p=0.955) was observed; However, the SVR of Koreans was higher with significance than that of Westerns (p<0.001) On the other hand, there was no difference what so ever, in SVR for genotype 2 amongst the different races. The SVR of combination therapy for the Korean chronic hepatitis C patients was similar to other Asians but higher than Westerns.

UR - http://www.scopus.com/inward/record.url?scp=84887522117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84887522117&partnerID=8YFLogxK

M3 - Article

VL - 60

SP - 306

EP - 314

JO - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

JF - The Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi

SN - 1598-9992

IS - 5

ER -